Re: [新聞] 《刺胳針》投書掀熱議 疾管署急澄清 台大
看到住院病患死亡率58.2%
正常人都會覺得這數據有問題
那段時期哪來這麼高的死亡率大家都不知道???
然後現在才被這兩個醫生發現???
其實這篇文章有註記58.2%這個數據的來源,來自於底下的文章
這是來自於林口長庚110名插管病患的研究
110病患中,有46例(佔41.8%)屬於Alpha變異株
64例(佔58.2%)屬於Omicron變異株
所以58.2%這數字並不是死亡率
這是很明顯的引用錯誤
Comparison of Clinical Characteristics and Mortality Outcome in Critical
COVID-19 Patients Infected with Alpha and Omicron Variants
This study included 110 critical patients with COVID-19 who required
intubation and intensive care unit (ICU) admission. Among these patients, 46
(41.8%) required intensive care during Alpha predominance period and 64
(58.2%) during the Omicron predominance period. The Alpha group had a higher
body mass index, had a longer ICU stay, and included more patients with acuterespiratory distress syndrome, and the Omicron group included more active
smokers, had more comorbidities, had worse initial laboratory data (includinghigher white blood cell counts, prothrombin time [PT], activated partial
prothrombin time, blood urine nitrogen levels, and creatine levels), and had
higher in-hospital mortality rates (40.6% vs 15.2%, p = 0.004). The
independent risk factors for in-hospital mortality, were Charlson ComorbidityIndex (CCI) 3 and higher PT and creatine levels.
--
說得好。PTT的IF有多少
不是人家引錯是你自己亂解讀,新聞內容就說
是住院治療的死亡率
疾管署跳針兩國死亡率,人家是從醫院收治比較
疾管署如果要針對論文的話可以比較收治標準
母數加一堆青少年 死亡率就低惹 西西
傻鳥只會看自己想看的啦
49
Re: [心得] 傳瑞德西韋試驗達標! 美股早盤大漲460點就在剛剛Lancet雜誌(醫學界三大期刊)發表的雙盲,多醫學中心,隨即分派實驗,瑞德西韋對嚴重COVID-19的治療結果。 先說結論: Our trial found that intravenous remdesivir did not significantly improve the time to clinical improvement, mortality, or time to clearance of virus in patients with serious COVID-19 compared with placebo 我們的臨床試驗發現靜脈注射瑞德西韋並沒有達到臨床症狀改善時間上的顯著差異、對死亡率、或者病毒清除也和安慰劑沒有顯著改善。 (20)31022-9/fulltext3
Re: [問卦] 輝瑞口服藥,是不是又...?這個歐美已經有資料啦~ 歐盟 (European Medicines Agency) 官網: 裡面What benefits of Paxlovid have been shown in studies? A main study involving patients with COVID-19 and at least one underlying![Re: [問卦] 輝瑞口服藥,是不是又...? Re: [問卦] 輝瑞口服藥,是不是又...?](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2022/nejm_2022.386.issue-15/nejmoa2118542/20220411/images/img_small/nejmoa2118542_f0.jpeg)
2
Re: [爆卦] COVID-19 棘蛋白會影響心臟細胞功能這篇看起來就是想去測感染PC 結果10MOI 還是沒感染 慘 後面扯了半天只要看兩個東西就好 "Using a highly sensitive ELISA, we detected S protein in the serum of COVID-19 patients (33.5 ± 8.3 ng/mL)" 他從病患血清只測到 ~40ng/mLX
Re: [問卦] 韓國omicron死亡率0.16%所以delta致死率應為0.16*5 ? 一般認為delta比alpha更加危險吧? 所以台灣alpha致死率為何破5? omicron來到台灣會不會也6到7倍外界平均死亡率?那也會破1吧? 以佛奇 omicron終將感染大部分人的判斷,台灣死亡會破2000*0.0016*6 嗎?![Re: [問卦] 韓國omicron死亡率0.16% Re: [問卦] 韓國omicron死亡率0.16%](https://i.imgur.com/8AWAiwHb.jpg)
Re: [問卦] Omicron是怎麼被洗成小感冒的???支持輕症 流感說的一般會拿歐美的數據來佐證重症 死亡都很低 但是我覺得他們忘了台灣有台灣的玩法 去年台灣爆發的應該是alpha株,死亡率大概有5? 但是alpha在國外也只有1左右啊 我是覺得,如果不對alpha在台灣死亡率為何數倍于國外做徹底的調查前還是不要貿然認為在台灣也是流感1
Re: [問卦] 各國漸漸開放,台灣是不是很尷尬?泰國已經開放 菲律賓2/10開放 越南預計下月底開放 日韓理論上應該4,5月那邊會考慮![Re: [問卦] 各國漸漸開放,台灣是不是很尷尬? Re: [問卦] 各國漸漸開放,台灣是不是很尷尬?](https://i.imgur.com/spPlGHIb.jpg)
![Re: [新聞] 《刺胳針》投書掀熱議 疾管署急澄清 台大 Re: [新聞] 《刺胳針》投書掀熱議 疾管署急澄清 台大](https://i.imgur.com/EwD9UHTb.png)